超重和肥胖痛风患者减重的系统综述:纵向研究证据
该系统综述检索六个数据库的纵向研究,评估超重/肥胖痛风患者减重的获益与风险。共纳入10项研究(含1项随机试验),平均减重3 kg至34 kg;对血尿酸(sUA)影响从-168至30 μmol/L,0%-60%患者达到sUA目标(<360 μmol/L),8项研究中6项(75%)显示对痛风发作有益。证据质量低至中等,短期减重手术后可能出现sUA和痛风发作的暂时性增加。
要点
- 减重对超重/肥胖痛风患者可能有益,但证据质量低至中等。
- 减重幅度3-34 kg,sUA变化-168至30 μmol/L,0%-60%达标。
- 短期减重手术后可能出现sUA和痛风发作的暂时性增加。
核心结论
- 现有证据支持超重/肥胖痛风患者减重,对sUA、达到sUA目标和痛风发作的证据质量分别为低、中、低。
- 短期可能出现不利效应,需开展严格的前瞻性研究( preferably 随机对照试验)。
研究设计与样本
- 系统综述检索六个数据库的纵向研究,纳入报告超重/肥胖痛风患者减重效果的研究。
- 从3991篇可能合格的研究中纳入10项(包括1项随机试验),干预包括饮食伴/不伴体力活动、减重手术、利尿剂、二甲双胍或无干预。
- 偏倚风险采用非随机干预研究偏倚风险评估工具,证据质量采用GRADE评估。
主要发现
- 平均减重范围为3 kg至34 kg。
- 对sUA的影响范围为-168至30 μmol/L,0%-60%患者达到sUA目标(<360 μmol/L)。
- 8项研究中有6项(75%)显示对痛风发作有益。
- 两项研究提示sUA、达到sUA目标和痛风发作存在剂量-反应关系。
- 短期减重手术后倾向于出现sUA和痛风发作的暂时性增加。
关键数值与推荐
- sUA目标为<360 μmol/L,达到该目标的比例为0%-60%。
- 平均减重范围为3 kg至34 kg,sUA变化范围为-168至30 μmol/L。
- 8项研究中6项(75%)显示对痛风发作有益。
临床怎么用
- 对于超重/肥胖痛风患者,减重可作为推荐干预,但需告知证据质量有限。
- 短期减重手术后应监测sUA和痛风发作,警惕暂时性升高。
局限性
- 研究间临床异质性大,无法进行meta分析。
- 纳入研究少且多为观察性研究,方法学质量低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Weight loss is commonly recommended for gout, but the magnitude of the effect has not been evaluated in a systematic review. The aim of this systematic review was to determine benefits and harms associated with weight loss in overweight and obese patients with gout. METHODS: We searched six databases for longitudinal studies, reporting the effect of weight loss in overweight/obese gout patients. Risk of bias was assessed using the tool Risk of Bias in Non-Randomised Studies of Interventions. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation. RESULTS: From 3991 potentially eligible studies, 10 were included (including one randomised trial). Interventions included diet with/without physical activity, bariatric surgery, diuretics, metformin or no intervention. Mean weight losses ranged from 3 kg to 34 kg. Clinical heterogeneity in study characteristics precluded meta-analysis. The effect on serum uric acid (sUA) ranged from -168 to 30 μmol/L, and 0%-60% patients achieving sUA target (<360 μmol/L). Six out of eight studies (75%) showed beneficial effects on gout attacks. Two studies indicated dose-response relationship for sUA, achieving sUA target and gout attacks. At short term, temporary increased sUA and gout attacks tended to occur after bariatric surgery. CONCLUSIONS: The available evidence is in favour of weight loss for overweight/obese gout patients, with low, moderate and low quality of evidence for effects on sUA, achieving sUA target and gout attacks, respectively. At short term, unfavourable effects may occur. Since the current evidence consists of a few studies (mostly observational) of low methodological quality, there is an urgent need to initiate rigorous prospective studies (preferably randomised controlled trials). SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42016037937.
引用
- Nielsen SM, Bartels EM, Henriksen M, et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis. 2017. PMID: 28866649. doi:10.1136/annrheumdis-2017-211472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。